Stoke Therapeutics (STOK) Invested Capital (2022 - 2025)
Historic Invested Capital for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $308.1 million.
- Stoke Therapeutics' Invested Capital rose 3273.92% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 3273.92%. This contributed to the annual value of $229.0 million for FY2024, which is 4352.83% up from last year.
- Per Stoke Therapeutics' latest filing, its Invested Capital stood at $308.1 million for Q3 2025, which was up 3273.92% from $334.9 million recorded in Q2 2025.
- Stoke Therapeutics' 5-year Invested Capital high stood at $350.1 million for Q1 2025, and its period low was $140.3 million during Q1 2024.
- Over the past 4 years, Stoke Therapeutics' median Invested Capital value was $224.3 million (recorded in 2022), while the average stood at $228.5 million.
- As far as peak fluctuations go, Stoke Therapeutics' Invested Capital crashed by 3436.5% in 2024, and later surged by 14944.35% in 2025.
- Stoke Therapeutics' Invested Capital (Quarter) stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 34.53% to $308.1 million in 2025.
- Its Invested Capital stands at $308.1 million for Q3 2025, versus $334.9 million for Q2 2025 and $350.1 million for Q1 2025.